Photo by CDC on Unsplash

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

MinervaXApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors Read more…